| dc.contributor | Castaneda-Arellano, R., Cellular and Molecular Biology Dept., CUCBA, University of Guadalajara, Zapopan, Jal., Mexico; Beas-Zarate, C., Cellular and Molecular Biology Dept., CUCBA, University of Guadalajara, Zapopan, Jal., Mexico; Feria-Velasco, A.I., Cellular and Molecular Biology Dept., CUCBA, University of Guadalajara, Zapopan, Jal., Mexico; Bitar-Alatorre, E.W., Traumatology Dept., County Carmen's Hospital, Guadalajara, Jalisco, Mexico; Rivera-Cervantes, M.C., Cellular and Molecular Biology Dept., CUCBA, University of Guadalajara, Zapopan, Jal., Mexico | |
| dc.description.abstract | Epilepsy is a disorder characterised by recurrent seizures and molecular events, including the activation of early expression genes and the post-translational modifications of functional proteins. These events lead to changes in neurogenesis, mossy fibre sprouting, network reorganisation and neuronal death. The role of these events is currently a matter of great debate, especially as they relate to protection, repair, or further brain injury. In recent years, accumulating data have supported the idea that erythropoietin (EPO) regulates biological processes including neuroprotection and neurogenesis in several diseases, such as epilepsy. This review summarises the role of EPO in some of the molecular mechanisms involved in these events that could direct a more detailed approach for its use as a therapeutic alternative in reducing epileptic seizures. | |
